Critical Analysis: Glucose Health (OTCMKTS:GLUC) and GE HealthCare Technologies (NASDAQ:GEHC)

Glucose Health (OTCMKTS:GLUC) and GE HealthCare Technologies (NASDAQ:GEHC) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Profitability

This table compares Glucose Health and GE HealthCare Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Glucose Health	-108.70%	N/A	N/A
GE HealthCare Technologies	10.11%	21.35%	5.91%

Earnings & Valuation

This table compares Glucose Health and GE HealthCare Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glucose Health	$380,000.00	20.99	-$320,000.00	($0.03)	-13.00
GE HealthCare Technologies	$20.63 billion	1.56	$2.08 billion	$4.56	15.43

GE HealthCare Technologies has higher revenue and earnings than Glucose Health. Glucose Health is trading at a lower price-to-earnings ratio than GE HealthCare Technologies, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

82.1% of GE HealthCare Technologies shares are held by institutional investors. 0.3% of GE HealthCare Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Glucose Health and GE HealthCare Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glucose Health	0	0	0	0	0.00
GE HealthCare Technologies	1	6	7	0	2.43

GE HealthCare Technologies has a consensus target price of $92.17, indicating a potential upside of 31.01%. Given GE HealthCare Technologies’ stronger consensus rating and higher probable upside, analysts plainly believe GE HealthCare Technologies is more favorable than Glucose Health.

Volatility & Risk

Glucose Health has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, GE HealthCare Technologies has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.

Summary

GE HealthCare Technologies beats Glucose Health on 13 of the 14 factors compared between the two stocks.

About Glucose Health

Glucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.

About GE HealthCare Technologies

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women’s health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women’s health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.